Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$70.09 - $111.29 $42.9 Million - $68.2 Million
-612,700 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $10.3 Million - $14.7 Million
93,700 Added 18.05%
612,700 $68.6 Million
Q2 2021

Aug 16, 2021

SELL
$100.84 - $161.89 $3.38 Million - $5.42 Million
-33,500 Reduced 6.06%
519,000 $84 Million
Q1 2021

May 17, 2021

BUY
$110.72 - $210.04 $11.1 Million - $21.2 Million
100,700 Added 22.29%
552,500 $67.3 Million
Q4 2020

Feb 16, 2021

SELL
$79.67 - $173.23 $14.2 Million - $30.9 Million
-178,204 Reduced 28.29%
451,800 $69.2 Million
Q3 2020

Nov 16, 2020

SELL
$78.5 - $100.64 $5.3 Million - $6.8 Million
-67,520 Reduced 9.68%
630,004 $52.7 Million
Q2 2020

Aug 14, 2020

BUY
$38.5 - $76.05 $5.63 Million - $11.1 Million
146,324 Added 26.55%
697,524 $51.3 Million
Q1 2020

May 15, 2020

SELL
$33.68 - $62.53 $7.25 Million - $13.5 Million
-215,178 Reduced 28.08%
551,200 $23.4 Million
Q4 2019

Feb 14, 2020

BUY
$36.68 - $73.13 $9.17 Million - $18.3 Million
249,978 Added 48.41%
766,378 $46.7 Million
Q3 2019

Nov 14, 2019

BUY
$40.99 - $52.56 $21.2 Million - $27.1 Million
516,400 New
516,400 $21.2 Million
Q4 2018

Feb 14, 2019

SELL
$22.73 - $42.34 $11.3 Million - $21 Million
-496,200 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$42.62 - $73.59 $16.7 Million - $28.8 Million
391,799 Added 375.28%
496,200 $29.2 Million
Q1 2018

May 15, 2018

BUY
$23.52 - $58.17 $2.46 Million - $6.07 Million
104,401 New
104,401 $4.77 Million
Q4 2017

Feb 14, 2018

SELL
$16.95 - $23.48 $6.31 Million - $8.74 Million
-372,191 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$16.75 - $20.66 $6.23 Million - $7.69 Million
372,191
372,191 $6.65 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.16B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.